A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate
Eli Lilly and Company
Summary
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.
Eligibility
- Age range
- 18–75 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * For Parts A, B, C, E, and F: Overtly healthy males or females as determined by medical history and physical examination * For Parts A, B, C, E, and F: Have a screening body mass index (BMI) in the range of 18.5 to 35 kilogram per square meter (kg/m²), inclusive, with no significant weight gain or loss in the past 3 months prior to screening * For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China * For Part D, participants must have a stable dose of medications…
Interventions
- DrugLY3971297
Administered SC
- DrugPlacebo
Administered SC
- DrugLY3971297 IV
Administered IV
Locations (7)
- CenExel ACTAnaheim, California
- Clinical Pharmacology of MiamiMiami, Florida
- ICON Early Phase ServicesSan Antonio, Texas
- Hakata ClinicFukuoka
- P-One ClinicHachiōji
- Clinical Research Hospital TokyoShinjuku-ku